# PET Study With [89Zr]-Df-CriPec® Docetaxel

> **NCT03712423** · PHASE1 · COMPLETED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 7 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Cripec Docetaxel

## Key facts

- **NCT ID:** NCT03712423
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-01
- **Primary completion:** 2020-03-25
- **Final completion:** 2020-05-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2020-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03712423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03712423, "PET Study With [89Zr]-Df-CriPec® Docetaxel". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03712423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*